CML-466 Asciminib Provides Durable Molecular Responses in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With the T315I Mutation: Updated Efficacy and Safety Data From a Phase I Trial

Timothy P. Hughes, Jorge E. Cortes, Delphine Réa, Michael J. Mauro, Andreas Hochhaus, Dong Wook Kim, Koji Sasaki, Fabian Lang, Michael C. Heinrich, Massimo Breccia, Michael Deininger, Yeow Tee Goh, Jeroen J.W.M. Janssen, Moshe Talpaz, Philipp le Coutre, Shruti Kapoor, Silvia Cacciatore, Fotis Polydoros, Nithya Agrawal, Francois Xavier Mahon

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'CML-466 Asciminib Provides Durable Molecular Responses in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With the T315I Mutation: Updated Efficacy and Safety Data From a Phase I Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences